✦ LIBER ✦

Combination of a dopamine agonist, MAO-B inhibitor and levodopa — a new strategy in the treatment of early Parkinson's disease

✍ Scribed by U. K. Rinne

Book ID: 114782838
Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 315 KB
Volume: 80
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1989.tb01797.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dopamine agonists in the treatment of ea

Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis

✍ William L. Baker; Dee Silver; C. Michael White; Jeffrey Kluger; Jeffrey Aberle; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 245 KB

Pramipexole — a new dopamine agonist for

Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease

✍ James P Bennett Jr.; Montford F Piercey 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Deprenyl (selegiline) combined with levo

Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease

✍ JAN PRESTHUS; ALAJOS HAJBA 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

Pharmacologic treatment of advanced Park

Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors

✍ Ripple Talati; Kurt Reinhart; William Baker; C. Michael White; Craig I. Coleman 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 228 KB

Tolerability and Safety of Ropinirole ve

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease

✍ Jaime Kulisevsky MD, PhD, Javier Pagonabarraga 📂 Article 📅 2010 🏛 Springer International Publishing AG 🌐 English ⚖ 287 KB

Levodopa alone and in combination with a

Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

✍ U. K. Rinne; E. Birket-Smith; E. Dupont; E. Hansen; M. Hyyppä; R. Marttila; B. M 📂 Article 📅 1975 🏛 Springer 🌐 English ⚖ 528 KB

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide prov